Ethris is a pioneering brand based in Planegg, just outside Munich, Germany. Founded by Dr. Carsten Rudolph and Prof.

Christian Plank, Ethris is at the forefront of establishing messenger RNA (mRNA) as a new drug modality. Leveraging their unique SNIM® RNA platform and proprietary lipidoid nanoparticle (LNP) formulation and delivery platform, Ethris offers highly versatile, multi-route, and multi-cargo delivery options for a range of drug candidates. Their focus is on developing therapeutics for respiratory viral infections and rare pulmonary diseases, as well as the next-generation of mRNA vaccines.

They aim to create vaccines that are mutation-agnostic, multivalent, and mucosal, in what they call the Triple-M concept. Ethris maintains a first-mover advantage through their differentiated nebulization technology for inhaled delivery directly to the respiratory tract. With their platforms, Ethris is poised to address significant unmet medical needs worldwide